Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live News

Jubilant Pharmova has appointed Daniel J. O`Connor as CEO of Jubilant Therapeutics Inc. step down subsidiary of the company. Powered by Capital Market - Live News

The board of Jubilant Pharmova at its meeting held on 31 October 2025 has approved the Grant of 1,506 Stock Options/ Restricted Stock Units (RSUs) to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.Powered by Capital Market - Live News

Net profit of Jubilant Pharmova rose 17.02% to Rs 120.30 crore in the quarter ended September 2025 as against Rs 102.80 crore during the previous quarter ended September 2024. Sales rose 12.38% to Rs 1957.80 crore in the quarter ended September 2025 as against Rs 1742.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1957.801742.20 12 OPM %17.4316.61 - PBDT300.90250.00 20 PBT196.10158.60 24 NP120.30102.80 17 Powered by Capital Market - Live News

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live News